Amoxicillin Bioequivalence Study Brazil - Fast
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Infections, Bacterial
Intervention: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL (Drug); Amoxil® 500mg/5mL powder for oral suspension (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
This study is prospective, open-label, randomized, crossover, single dose, with 02
treatments, 02 sequences and 02 periods. The volunteers received, in each period, the
reference or the test formulation, according to the randomization list, under fasting
conditions, in order to evaluate if the reference and test formulations are bioequivalent.
Clinical Details
Official title: Evaluation of Pharmaceutical Bioequivalence of Amoxicillin Trihydrate - Clamoxyl 500mg/5mL (Glaxo Wellcome Production.) in the Form Powder for Oral Suspension Versus Amoxil ® 500mg/5mL (GlaxoSmithKline Mexico SA) in the Form of Powder for Oral Suspension in Healthy Volunteers and Fasting, Using Techniques of Liquid Chromatography
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label
Primary outcome: Area Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) to t (Last Measurable Concentration) (AUC0-t)Maximum Observed Concentration of Drug Through Time (Cmax) Area Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) Extrapolated to Infinity (AUC0-inf) Time of Maximum Observed Concentration (Tmax) Percentage of AUC0-inf That is Due to Extrapolation From the Time of the Last Measurable Concentration to Infinity (AUC%Extrapolation) Terminal Half-life (T1/2_Kel) First-order Rate Constant Associated With the Terminal Portion of the Curve (Kel)
Detailed description:
This study is prospective, open-label, randomized, crossover, single dose, with 02
treatments, 02 sequences and 02 periods. The objective is to confirm if two formulations of
Amoxicillin trihydrate, in the form powder for oral suspension, are bioequivalent. The test
product is Amoxicillin trihydrate - Clamoxyl 500mg/5mL (Glaxo Wellcome Production.) in the
form powder for oral suspension and reference product is Amoxil ® 500mg/5mL (GlaxoSmithKline
Mexico SA) in the form of powder for oral suspension. Twenty eight healthy volunteers, of
both genders, were evaluated. The volunteers received, in each period, the reference or the
test formulation, according to the randomization list, under fasting conditions. In each
period blood samples are collected in the following times: 0. 00 (prior to administration of
medication); 0. 25; 0. 50; 0. 75; 1. 00; 1. 25; 1. 50; 1. 75; 2. 00; 2. 50; 3. 00; 4. 00; 5. 00; 6. 00;
8. 00 (after administration of medication). The comparative bioavailability of the two
formulations was evaluated based in statistical comparisons of relevant pharmacokinetic
parameters, obtained from data of drug concentrations in blood.
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age between 18 and 50 years
- Body mass index between 18,5 and 25,0, can vary up to 15% for the upper limit (18,5
and 28,75)
- Good health conditions
- Obtain signed informed consent
Exclusion Criteria:
- Results of laboratory tests outside the normal limits, unless they are considered
clinically irrelevant
- The volunteers who underwent surgery or who were hospitalized for any reason before
the start of the study will be reviewed by the physician on admission in the study,
observing a period of exclusion of 4 to 8 weeks
- Positive test for hepatitis B, hepatitis C or HIV in pre study evaluation
- Known hypersensitivity to the study drug or to compounds chemically related
- Use of experimental drug or participation in any clinical study within 6 months prior
to study initiation
- Use of regular medication within 2 weeks prior to study initiation
- History of alcohol or drugs abuse or intake of alcohol within 24 hours prior to the
period of confinement
- Consume of inductive drugs and/or enzymatic inhibitors (CYP450 - hepatic), that are
toxic for the organism or presenting long half-life's elimination within 30 days
prior to study initiation
- Use of MAO and serotonin reuptake inhibitors within 2 weeks prior to study initiation
- Volunteers with psychiatric or psychological illness unless they are considered
clinically irrelevant by the investigator
- History or presence of hepatic, renal or gastrointestinal illness or other condition
that interferes on drug's absorption, distribution, excretion or metabolism
- History of neurological, endocrine, pulmonary, hematologic, immune, brain, metabolic
or cardiovascular illness
- Hypo or hypertension of any etiologic that needs pharmacologic treatment
- History or clinical case of myocardial infarction, angina and/or heart failure
- The volunteer donated or lost 450 mL or more of blood within the 3 months prior to
the study initiation
- The volunteer has any condition that obstructs his/her participation in the study
according the investigator's judgement
- Smoking
- Positive beta HCG exam for women
- Breastfeeding women
- Women making use of contraceptive medication
Locations and Contacts
GSK Investigational Site, Goiania, Goiás, Brazil
Additional Information
Starting date: May 2011
Last updated: January 4, 2013
|